LEO Pharma Signs US$402 M Dermatology Deal with JW Pharmaceutical

By Michelle Liu & Keval Haria

Pharma Deals Review: Vol 2018 Issue 9 (Table of Contents)

Published: 19 Sep-2018

DOI: 10.3833/pdr.v2018.i9.2360     ISSN: 1756-7874

Section: Licensing



Continuing to build its dermatology portfolio, LEO Pharma has entered into a global licensing agreement with JW Pharmaceutical gaining exclusive rights to develop and commercialise an atopic dermatitis drug candidate, JW1601...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details